Tenderskhoj
Germany
- Healthcare & Medical Medical
LOCATION SUMMARY DEADLINE
Germany Conclusion Not Excluding Drug Discount Agreement. According To § 130a Paragraph. 8 Sgb V Through An Openhouse Model For The Active Ingredient Interferon Beta1a (atccode According To Who
 30 Jun 2025
Germany Completion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Or 130c Paragraph 1 Sgb V For The Period From July 1st, 2024 To The I.d.r. June 30, 2026
 06 Jun 2024
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph. 8/130c Abs. 1 Sgb V On Medicinal Products With The Active Ingredient Sirolimus (l04ah01) Within The Framework Of A So-called Openhouse Model.
 30 Apr 2026
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130 A Paragraph. 8 Sgb V With The Active Ingredient Bevacizumab
 10 May 2026
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph. 8/130c Abs. 1 Sgb V On Medicinal Products With The Active Ingredient Mebeverin (a03aa04) Within The Framework Of A So-called Openhouse Model.
 30 Apr 2026
Germany 6002636912 Various Vaccines
 18 Jun 2024
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph. 8/130c Abs. 1 Sgb V On Medicinal Products With The Active Ingredient Lipegfilgrastim (l03aa14) Within The Framework Of A So-called Openhouse Model.
 30 Apr 2026
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130 A Paragraph. 8 Sgb V With The Active Ingredient Ranibizumab
 10 May 2026
Germany Procurement Procedure For The Conclusion Of A Framework Agreement For The Supply Of Chemicals
 28 Jun 2024
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph. 8/130c Abs. 1 Sgb V On Medicinal Products With The Active Ingredient Lipegfilgrastim (l03aa14) Within The Framework Of A So-called Open-house Model.
 01 May 2026